Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Sifalimumab in SLE or Myositis
NCT00979654Phase 2Completed
- Sponsor
- MedImmune
- Start
- Aug 2010
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of sifalimumab in systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), sponsored by MedImmune. Started Aug 2010; status: completed.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT00979654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00979654.